Novo Nordisk's announcement this week that they will be investing £115m in a new research centre in Oxford is testimony to the quality of the UK talent pool in the pharmaceutical space.
This is further evidence of the trends highlighted in our Pharma Fast 50 report, especially that pharmaceutical innovation is thriving in the UK "despite short-term uncertainty associated with Brexit. A combination of great science, an extensive talent pool and availability of capital, together with the presence of major global pharma players, will continue to drive the growth of pharma businesses in the UK."
Our full report can be read here:
Danish pharmaceutical giant Novo Nordisk is to invest about £115m over 10 years in a new research centre in Oxford, in a move described by the government as a “vote of confidence” in post-Brexit Britain